PTC THERAPEUTICS, INC. - 8-K Filing
PTC Therapeutics completed acquisition of ST-920 gene therapy for Fabry disease and expects BLA submission in Q4 2026. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Information, 9.01 Financial Statements and Exhibits)
Tickers: $PTCT